PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Endo International PLC ( ) from 2018 to Jun 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Endo International PLC stock (LTS:0Y5F) PE ratio as of Jun 21 2024 is 0. More Details

Endo International PLC (LTS:0Y5F) PE Ratio (TTM) Chart

To

Endo International PLC (LTS:0Y5F) PE Ratio (TTM) Historical Data

Total 1272
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Endo International PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-22 At Loss 2024-03-11 At Loss
2024-05-10 At Loss 2024-03-08 At Loss
2024-05-09 At Loss 2024-03-07 At Loss
2024-05-08 At Loss 2024-03-06 At Loss
2024-05-07 At Loss 2024-03-05 At Loss
2024-05-06 At Loss 2024-03-04 At Loss
2024-05-03 At Loss 2024-03-01 At Loss
2024-05-02 At Loss 2024-02-29 At Loss
2024-05-01 At Loss 2024-02-28 At Loss
2024-04-30 At Loss 2024-02-27 At Loss
2024-04-29 At Loss 2024-02-26 At Loss
2024-04-26 At Loss 2024-02-23 At Loss
2024-04-25 At Loss 2024-02-22 At Loss
2024-04-24 At Loss 2024-02-21 At Loss
2024-04-23 At Loss 2024-02-20 At Loss
2024-04-22 At Loss 2024-02-19 At Loss
2024-04-19 At Loss 2024-02-16 At Loss
2024-04-18 At Loss 2024-02-15 At Loss
2024-04-17 At Loss 2024-02-14 At Loss
2024-04-16 At Loss 2024-02-13 At Loss
2024-04-15 At Loss 2024-02-12 At Loss
2024-04-12 At Loss 2024-02-09 At Loss
2024-04-11 At Loss 2024-02-08 At Loss
2024-04-10 At Loss 2024-02-07 At Loss
2024-04-09 At Loss 2024-02-06 At Loss
2024-04-08 At Loss 2024-02-05 At Loss
2024-04-05 At Loss 2024-02-02 At Loss
2024-04-04 At Loss 2024-02-01 At Loss
2024-04-03 At Loss 2024-01-31 At Loss
2024-04-02 At Loss 2024-01-30 At Loss
2024-04-01 At Loss 2024-01-29 At Loss
2024-03-29 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-15 At Loss
2024-03-15 At Loss 2024-01-12 At Loss
2024-03-14 At Loss 2024-01-11 At Loss
2024-03-13 At Loss 2024-01-10 At Loss
2024-03-12 At Loss 2024-01-09 At Loss

Endo International PLC (LTS:0Y5F) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.